Corneal Epithelial Allograft From Living-related Donor for LSCD

Inclusion Criteria: 1. LSCD secondary to ocular burns, with the duration of disease of at least 24 months at the time of screening visit; 2. Presence of superficial neo-vascularization affecting at least 2 cornea quadrants and involving central cornea; 3. Having a human leukocyte antigen (HLA)-matched living-related donor (≥4/6 HLA-A/B/DR matched); 4. Informed consent signed by patient or legal guardian. Having the ability to comply with study assessments for the full duration of the study. Exclusion Criteria: Recipients: 1. LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement; 2. LSCD by ocular surface disorders other than ocular burn; 3. Eyelids malposition; 4. The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm; 5. High myopia with a spherical equivalent of -15.0 D or less; 6. Corneal or ocular surface infection within 30 days prior to study entry; 7. Ocular surface malignancy; 8. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%; 9. Renal failure with creatinine clearance\< 25ml/min; 10. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L; 11. Platelet levels \< 150,000 or \> 450,000 per microliter; 12. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female); 13. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy; 14. Pregnancy (positive test) or lactation; 15. Participation in another simultaneous medical investigation or clinical trial; 16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening; 17. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases; 18. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye; 19. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent; 20. Signs of current infection, including fever and treatment with antibiotics; 21. Active immunological diseases; 22. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries. Donors: 1. Cornea diseases (epithelial defects, neovascularization, etc.); 2. Eyelids malposition; 3. The center corneal thickness\<450µm, the depth of corneal opacity \> 150µm; 4. High myopia with a spherical equivalent of -15.0 D or less; 5. Corneal or ocular surface infection within 30 days prior to study entry; 6. Ocular surface malignancy; 7. Uncontrolled diabetes with most recent Hemoglobin A1c greater than 8.5%; 8. Renal failure with creatinine clearance\< 25ml/min; 9. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L; 10. Platelet levels \< 150,000 or \> 450,000 per microliter; 11. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female); 12. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy; 13. Pregnancy (positive test) or lactation; 14. Participation in another simultaneous medical investigation or clinical trial; 15. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening; 16. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases; 17. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye; 18. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent; 19. Signs of current infection, including fever and treatment with antibiotics; 20. Active immunological diseases; 21. History of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.